Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPGM | P07738 | 3/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.35 |
| ▸ | GPR52 | Q9Y2T5 | 6/20 | 0.35 |
| ▸ | RARA | P10276 | 1/20 | 0.34 |
| ▸ | RARB | P10826 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | COMT | P21964 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24271803 | 0.86 | BPGM (0.57) | BPGMGPR52PPARDKDM4EMAPT | |
| SCHEMBL24271804 | 0.74 | POLB (0.41) | GPR52GAARAB9AKDM4ELMNA | |
| SCHEMBL24271848 | 0.70 | BPGM (0.55) | BPGMPPARDSMN1; SMN2 | |
| SCHEMBL24271979 | 0.70 | MEN1 (0.41) | GPR52 | |
| SCHEMBL24271786 | 0.70 | BPGM (0.58) | BPGMGPR52PPARDKDM4EMAPT | |
| SCHEMBL24271914 | 0.70 | KDM4E (0.43) | BPGMGPR52GAARAB9ACOMT | |
| SCHEMBL30445389 | 0.70 | KDM4E (0.43) | BPGMGPR52GAARAB9ACOMT | |
| SCHEMBL24272071 | 0.69 | BPGM (0.56) | BPGMGPR52PPARDKDM4EMAPT | |
| SCHEMBL24271932 | 0.68 | BPGM (0.63) | BPGMGPR52RARARARBGAA | |
| SCHEMBL24271817 | 0.68 | MEN1 (0.55) | GAACOMTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION | 2023-11-02 | — | — | US | disclosed |
| WO-2022056447-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | BPGM, PGAM1, PGM2 | BPGM 1/4885NOTUM 2259/4885PTGER4 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.